Columna Capital to Acquire Evidenze Group From Buenavista Equity Partners

Why It Matters

The deal deepens Columna’s capabilities in outsourced pharma services, positioning it to capture rising demand as drug developers outsource non‑core functions, thereby accelerating industry consolidation.

Key Takeaways

• Columna Capital announces acquisition of Evidenze Group.
• Evidenze offers pan‑European outsourced pharma services.
• Deal transfers ownership from Buenavista Equity Partners.
• Acquisition strengthens Columna’s presence in pharma outsourcing.
• Financial terms of the transaction were not disclosed.

Pulse Analysis

Columna Capital has built a reputation for backing high‑growth life‑science businesses, and its latest move underscores a strategic push into the outsourced pharmaceutical services arena. The global pharma outsourcing market, valued at over $150 billion, is projected to expand at a compound annual growth rate of roughly 7% through 2028, driven by cost pressures, the need for speed-to-market, and regulatory complexity. By adding Evidenze’s pan‑European platform, Columna gains immediate access to a network of specialized service sites, enhancing its ability to offer end‑to‑end solutions for drug developers seeking to outsource clinical trial management, regulatory affairs, and supply‑chain logistics.

Evidenze’s portfolio includes clinical‑trial site management, data‑capture services, and regulatory submission support across more than 20 European countries. Its integrated model allows pharmaceutical firms to streamline operations, reduce overhead, and navigate divergent national regulations with a single point of contact. The acquisition not only expands Columna’s geographic reach but also diversifies its service offering, positioning the combined entity to compete with larger, multi‑national CROs that dominate the market. This synergy is expected to generate cross‑selling opportunities and operational efficiencies, potentially improving margins for both existing and new portfolio companies.

Industry observers view the transaction as a bellwether for continued consolidation in pharma outsourcing. As big‑pharma firms increasingly outsource peripheral activities to focus on core R&D, service providers that can demonstrate scale, regulatory expertise, and geographic breadth become attractive targets. Columna’s investment in Evidenze may prompt further M&A activity, encouraging other private‑equity groups to seek similar platforms. In the longer term, the combined capabilities could accelerate innovation cycles by reducing time and cost barriers for drug development, ultimately benefiting patients and shareholders alike.

Deal Summary

Columna Capital announced it will acquire Evidenze Group, a pan‑European outsourced pharma services platform, from its current owner Buenavista Equity Partners. The terms of the transaction were not disclosed. The deal was reported on May 5, 2026.